Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

Response to today's CMA fines on anti-competitive agreements


Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said:

"It is wholly unacceptable for companies to manipulate the market artificially to increase the price of generic medicines. The BGMA unreservedly condemns this sort of behaviour. It is the raison d’être of the generic medicines industry to decrease medicines prices through competition and thus to increase access to medicines for patients. The BGMA is proud of the fact that generic medicines prices in the UK are the lowest in Europe. This sort of behaviour is wholly incompatible with our mission. 

“We note that the behaviour involved is historic, and that our member company Accord-UK was not involved, but has assumed liability through acquisition."